Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation
Journal of Medical Internet Research · 05.02.2025 · 27 · e62836
DOI: 10.2196/62836 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Journal of Medical Internet Research, online erschienen am 05.02.2025. Verfasst von Hui Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing…. Hauptthemen laut MEDLINE: Dermatomyositis, Lung Diseases, Interstitial, Algorithms, Interferon-Induced Helicase, IFIH1. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Patients with antimelanoma differentiation–associated gene 5 antibody–positive dermatomyositis–associated interstitial lung disease (anti-MDA5+DM-ILD) are susceptible to rapidly progressive interstitial lung disease (RP-ILD) and have a high risk of mortality. There is an urgent need for a reliable prediction model, accessible via an easy-to-use web-based tool, to evaluate the risk of death.
Objective
This study aimed to develop and validate a risk prediction model of 3-month mortality using machine learning (ML) in a large multicenter cohort of patients with anti-MDA5+DM-ILD in China.
Methods
In total, 609 consecutive patients with anti-MDA5+DM-ILD were retrospectively enrolled from 6 hospitals across China. Patient demographics and laboratory and clinical parameters were collected on admission. The primary endpoint was 3-month mortality due to all causes. Six ML algorithms (Extreme Gradient Boosting [XGBoost], logistic regression (LR), Light Gradient Boosting Machine [LightGBM], random forest [RF], support vector machine [SVM], and k-nearest neighbor [KNN]) were applied to construct and evaluate the model.
Results
After applying inclusion and exclusion criteria, 509 (83.6%) of the 609 patients were included in our study, divided into a training cohort (n=203, 39.9%), an internal validation cohort (n=51, 10%), and 2 external validation cohorts (n=92, 18.1%, and n=163, 32%). ML identified 8 important variables as critical for model construction: RP-ILD, erythrocyte sedimentation rate (ESR), serum albumin (ALB) level, age, C-reactive protein (CRP) level, aspartate aminotransferase (AST) level, lactate dehydrogenase (LDH) level, and the neutrophil-to-lymphocyte ratio (NLR). LR was chosen as the best algorithm for model construction, and the model demonstrated excellent performance, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.866, a sensitivity of 84.8%, and a specificity of 84.4% on the validation data set and an AUC of 0.90, a sensitivity of 85.0%, and a specificity of 83.9% on the training data set. Calibration curves and decision curve analysis (DCA) confirmed the model’s accuracy and clinical applicability. Moreover, the model showed strong predictive performance in the external validation cohorts (cohort 1: AUC=0.836, 95% CI 0.754-0.916; cohort 2: AUC=0.915, 95% CI 0.871-0.959), indicating good generalizability. This model was integrated into a web-based tool to predict the 3-month mortality for patients with anti-MDA5+DM-ILD.
Conclusions
We successfully developed a robust clinical prediction model and an accompanying web tool to estimate the 3-month mortality risk for patients with anti-MDA5+DM-ILD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Pulmonary and Critical Care Medicine, Seventh Affiliated Hospital, Sun Yatsen University, Shenzhen, China.
- Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, China.
- Department of Respiratory and Critical Care Medicine, Third People's Hospital of Chengdu, Chengdu, China.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
- National Center for Respiratory Medicine, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Hui Li, Ruyi Zou, Hongxia Xin, Ping He, Bin Xi, Yaqiong Tian, Qi Zhao, Xin Yan, Xiaohua Qiu, Yujuan Gao, Yin Liu, Min Cao, Bi Chen, Qian Han, Juan Chen, Guochun Wang, Hourong Cai
Zitieren
APA
Li, H., Zou, R., Xin, H., He, P., Xi, B., Tian, Y., Zhao, Q., Yan, X., Qiu, X., Gao, Y., Liu, Y., Cao, M., Chen, B., Han, Q., Chen, J., Wang, G., & Cai, H. (2025). Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation. Journal of Medical Internet Research, 27, e62836. https://doi.org/10.2196/62836
Vancouver
Li H, Zou R, Xin H, He P, Xi B, Tian Y, et al. Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation. Journal of Medical Internet Research. 2025;27:e62836. doi:10.2196/62836
BibTeX
@article{Li2025,
author = {Li, Hui and Zou, Ruyi and Xin, Hongxia and He, Ping and Xi, Bin and Tian, Yaqiong and Zhao, Qi and Yan, Xin and Qiu, Xiaohua and Gao, Yujuan and Liu, Yin and Cao, Min and Chen, Bi and Han, Qian and Chen, Juan and Wang, Guochun and Cai, Hourong},
title = {Mortality Risk Prediction in Patients With Antimelanoma Differentiation–Associated, Gene 5 Antibody–Positive, Dermatomyositis–Associated Interstitial Lung Disease: Algorithm Development and Validation},
journal = {Journal of Medical Internet Research},
year = {2025},
volume = {27},
pages = {e62836},
doi = {10.2196/62836}
}
EUVIMED